European Commission funds research 'hidden nature' of codeine misuse
King’s College London is a partner in a 2 million euro multinational research project into codeine use, misuse and dependence, funded by the European Commission.
‘CODEMISUSED’’ is a four-year project which will involve researchers from King’s College London’s Florence Nightingale School of Nursing & Midwifery (FNSNM) and Institute of Psychiatry (IoP), working with the Waterford Institute of Technology in Ireland, the Medical Research Council (MRC) of South Africa and three national pharmacy companies in Ireland, UK and South Africa, in a collaborative effort between drug, medical and health researchers, and that of pharmacy practitioners.
Professor Ian Norman (Deputy Head, FNSNM) and Dr Paolo Deluca (Senior Research Fellow, National Addiction Centre, IoP) will both play leading roles in the research. They will work for periods in South Africa and Ireland and will host academics from the other partners at King’s College London for the first two years of the project.
Professor Norman said, “Codeine is currently the most commonly consumed opiate worldwide and since 2010, the European Monitoring Centre for Drugs and Drug Addiction and the International Narcotics Control Board has been concerned about the misuse of prescribed and over the counter medication. But very little is known about patterns of codeine use.
“What we suspect is that a variety of sub groups exist in the form of the elderly, youth, parents, recreational, problematic and opiate dependent drug users, each with their own motives, patterns and outcomes for use. Our research will develop codeine user profiles to inform the design of protective mechanisms to track, monitor, support and refer codeine misusers and inform the design of treatment interventions”.
Dr Deluca, the King’s lead for the project said, “Codemisused aims to estimate levels of therapeutic and non-therapeutic codeine use, misuse and dependence in partner countries. Our study will investigate the ‘hidden nature’ of codeine misuse – as a legitimate product, the extent of codeine misuse is not adequately reflected in national or international prevalence or treatment data. The unprecedented range of expertise we are bringing together in this project reflects the complex nature of the issue – users access codeine through prescriptions, over-the-counter and web-based sales, and understanding the profile of users and scale of the problem will require collaboration with pharmacists, GPs, pain management specialists and addiction treatment providers.
“Our findings will have a distinct impact on EU medicinal, dispensing, staff training and treatment standards and national pharmacy practice policies. It will give doctors, nurses, community pharmacists and other health professionals from partner countries a fuller understanding of the scale of codeine use and will enable the pharmacies, as the primary point of sale, to begin to address the problems associated with misuse and dependence.”
*** ENDS ***
For more information or interview and comment opportunities, contact:
Oliver Stannard
Communications Officer
Florence Nightingale School of Nursing & Midwifery, King’s College London
T: 020 7848 3062
E: oliver.stannard@kcl.ac.uk